Kynurenic acid and schizophrenia

Advances in Experimental Medicine and Biology

Volumn 527, Issue , 2003, Pages 155-165

  Erhardt, Sophie ^a   Schwieler, Lilly ^b   Engberg, Göran ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ENZYME INHIBITOR; HALOPERIDOL; KETAMINE; KYNURENIC ACID; PNU 156561 A; UNCLASSIFIED DRUG;

ANESTHESIOLOGICAL TECHNIQUES; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; MESENCEPHALON; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALIA;

EID: 1042268019     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0135-0_18     Document Type: Conference Paper

References (48)

1. W.T. Carpenter Jr and R.W. Buchanan, Schizophrenia, N. Engl. J. Med. 330, 681-690 (1994).
2. P. Asherson, R. Mant and P. McGuffin, Genetics and schizophrenia. In: Schizophrenia (Hirsch SR, Weinberger DR eds) Oxford: Blackwell Science 253-274 (1996).
3. E. Armstrong, A. Schleicher, H. Omran, M. Curtis and K. Zilles, The ontogeny of human gyrification, Cereb. Cortex 5, 56-63 (1995).
4. B.T. Woods, Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiatry 155, 1661-1670 (1998).
5. H.Y. Meltzer, Long-term effects of neuroleptic drugs on the neuroendocrine system, Adv. Biochem. Psychopharmacol. 40, 59-68 (1985).
6. A.Carlsson, The current status of the dopamine hypothesis of schizophrenia, Neuropsychopharmacology 1, 179-186 (1988).
7. H.D. Brenner, S.J. Dencker, M.J. Goldstein, J.W. Hubbard, D.L. Keegan, G. Kruger, F. Kulhanek, R.P. Liberman, U. Malm and K.K. Midha, Defining treatment refractoriness in schizophrenia, Schizophr. Bull. 16, 551-561 (1990).
8. A. Carlsson and M. Lindqvist, Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol. Toxicol. 20, 140-144 (1963).
9. L. Farde, F.A. Wiesel, S. Stone-Elander, C. Halldin, A.L. Nordstrom, H. Hall and G. Sedvall, D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride, Arch. Gen. Psychiatry 47, 213-219 (1990).
10. A. Abi-Dargham, J. Rodenhiser, D. Printz, Zea-Y. Ponce, R. Gil, L.S. Kegeles, R. Weiss, T.B. Cooper, J.J. Mann, R.L. Van Heertum, J.M. Gorman and M. Laruelle, From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia, Proc. Natl. Acad. Sci. U.S.A. 97, 8104-8109 (2000).
11. D.H. Ingvar and G. Franzen, Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia, Acta Psychiatr. Scand. 50, 425-462 (1974).
12. F, Karoum, C.N. Karson, L.B. Bigelow, W.B. Lawson and R.J. Wyatt, Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia, Arch. Gen. Psychiatry 44, 604-607 (1987).
13. D.B. Carr and S.R. Sesack, GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex, Synapse 38, 114-123 (2000).
14. A.A. Grace, Phasic versus tonic dopamine release and the modulation of dopamine systems responsivity: A hypothesis for the etiology of schizophrenia, Neuroscience 41, 1-24 (1991).
15. T.H. Svensson, Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain. Res. Brain Res. Rev. 31, 320-329 (2000).
16. A. Carlsson, N. Waters, S. Waters and M.L. Carlsson, Network interactions in schizophrenia - therapeutic implications. Brain Res. Rev. 31, 342-349 (2000).
17. F.E. Greifenstein, M. DeVault, J. Yoshitake and J.E. Gajewski, A study of 1-arul cyclo hexyl amine for analgesia, Anesth. Analg. 37, 283-294 (1958).
18. S.N. Pradhan, Phencyclidine (PCP): some human studies, Neurosc., Biobehav. Rev. 8, 493-501 (1984).
19. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb and R. Kelly, Study of a new schizophrenomimetic drug - Seemyl, Arch. Neurol. Psychiat. 81, 363-369 (1959).
20. J.A. Yesavage and A.M. Freman, Acute phencyclidine (PCP) intoxication: psychopathology and prognosis, J. Clin. Psychiatry 39, 664-666 (1978).
21. J. Grotta, W. Clark, B. Coull, L.C. Pettigrew, B. Mackay, L.B. Goldstein, I. Meissner, D. Murphy and L. LaRue, Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial, Stroke 26, 602-5 (1995).
22. E.D. French, A. Mura and T. Wang, MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists, Synapse 13, 108-116 (1993).
23. E.D. French, Phencyclidine and the midbrain dopamine system: electrophysiology and behavior, Neurotoxicol. Teratol. 16, 355-362 (1994).
24. E. Carboni, A. Imperato, L. Perezzani and G. Di Chiara, Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats, Neuroscience 28, 653-661 (1989).
25. P. Hertel, J.M. Mathe, G.G. Nomikos, M. Iurlo, A.A. Mathe and T.H. Svensson, Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat, Behav. Brain Res. 72, 103-114 (1995).
26. J.D. Jentsch and R.H. Roth, The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia, Neuropsychopharmacol. 20, 201-225 (1999).
27. D.R. Weinberger, K.F. Berman and B.P. Illowsky, Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism, Arch. Gen. Psychiatry 45, 609-615 (1988).
28. M.A. Geyer and D.L. Braff, Startle habituation and sensorimotor gating in schizophrenia and related animal models, Schizophr. Bull. 13, 643-668 (1987).
29. D.L. Braff, C. Grillon and M.A. Geyer, Gating and habituation of the startle reflex in schizophrenic patients, Arch. Gen. Psychiatry 49, 206-215 (1992).
30. V.P. Bakshi, M. Tricklebank, H.C. Neijt, V. Lehmann-Masten and M.A. Geyer, Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats, J. Pharmacol. Exp. Ther. 288, 643-652 (1999).
31. T.W. Stone, Neuropharmacology of quinolinic and kynurenic acids, Pharmacol. Rev. 45, 309-379 (1993).
32. P.J. Birch, C.J. Grossman and A.G. Hayes, Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor, Eur. J. Pharmacol. 154, 85-87 (1988).
33. F. Moroni, P. Russi, G. Lombard, M. Beni and V. Carla, Presence of kynurenic acid in the mammalian brain, J. Neurochem. 51, 177-180 (1988).
34. W.A. Turski, M. Nakamura, W.P. Todd, B.K. Carpenter, W.O. Whetsell Jr and R. Schwarcz, Identification and quantification of kynurenic acid in human brain tissue, Brain Res. 454, 164-169 (1988).
35. C. Speciale, H.Q. Wu, M. Cini, M. Marconi, M. Varasi and R. Schwarcz, (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats, Eur. J. Pharmacol. 315, 263-267 (1996).
36. S. Erhardt, H. Öberg and G. Engberg, Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons, Naunyn-Schmiedeberg's Arch. Pharmacol. 363, 21-27 (2001).
37. S. Erhardt, K. Blennow, C. Nordin, E. Skogh, L.H. Lindstrom and G. Engberg, Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia, Neurosci. Lett. 313, 96-8 (2001).
38. S. Erhardt and G. Engberg, Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid, Acta Physiol. Scand. 175, 45-53 (2002).
39. A.A. Grace and B.S. Bunney, The control of firing pattem in nigral dopamine neurons: single spike firing, J. Neurosci. 4, 2866-2876 (1984).
40. A.A. Grace and B.S. Bunney, The control of firing pattern in nigral dopamine neurons: burst firing, J. Neurosci. 4, 2877-2890 (1984).
41. H.E. Scharfman, J.H. Goodman and R. Schwarcz, Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro, Amino Acids 19, 283-297 (2000).
42. S. Erhardt, J.M. Mathe, K. Chergui, G. Engberg, and T.H. Svensson, GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo, Naunyn Schmiedebergs Arch. Pharmacol. 365, 173-180 (2002).
43. R. Schwarcz, A. Rassoulpour, H.Q. Wu, D. Medoff, C.A. Tamminga and R.C. Roberts, Increased cortical kynurenate content in schizophrenia, Biol. Psychiatry 50, 521-530 (2001).
44. G. Ceresoli-Borroni, H.Q. Wu, P. Guidetti, A. Rassoulpour, R.C. Roberts and R. Schwarcz, Chronic haloperidol administration decreases kynurenic acid levels in rat brain, Soc. Neurosci. Abstr. 25, 727-728 (1999).
45. J.B. Gramsbergen, P.S. Hodgkins, A. Rassoulpour, W.A. Turski, P. Guidetti and R. Schwarcz, Brain-specific modulation of kynurenic acid synthesis in the rat, J. Neurochem. 69, 290-298 (1997).
46. A. Rassoulpour, H.Q. Wu, C. Hilmas, E.X. Albuquerque, R. Schwarcz, Repeated nicotine administration results in biphasic charges in kynurenate levels in the rat brain, Soc. Neurosci. Abstr. 26, 526.4 (2000).
47. T.H. Svensson, J.M. Mathe, J.L. Andersson, G.G. Nomikos, B.E. Hildebrand and M. Marcus, Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism, J. Clin. Psychopharmacol. 15(1 Suppl 1), 11S-18S (1995).
48. U. Heresco-Levy, D.C. Javitt, M. Ermilov, G. Silipo and J. Shimoni, Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia, Int. J. Neuropsychopharmacol. 1, 131-135 (1998).